In the Claims:

Please cancel claim 33, 46 and 54 to 65 without prejudice and amend claims 32, 34, 42, 43, 44, 45, 47, 51, 52 and 53 as follows:

Claims 1 to 31 (canceled).

32(currently amended). A method of manufacturing a bioadhesive tablet for controlling testosterone blood level in a person for therapeutic purposes, said method comprising embedding testosterone undecanoate alone or a mixture of testosterone undecanoate and testosterone in ~~and/or one or more testosterone ester, separately or together, in~~ an organic polymer, optionally together with at least one auxiliary agent, by a spray-drying process, so as to form an amorphous active ingredient premix ~~premix;~~

~~wherein said one or more testosterone ester comprises a respective carboxylic acid radical with from 1 to 20 carbon atoms~~.

33(canceled).

34(currently amended). The method as defined in claim 32, wherein said amorphous active ingredient premix comprises said mixture of said testosterone undecanoate and said testosterone ~~and said one or more testosterone ester~~ in a ratio of said testosterone to said testosterone undecanoate ~~one or more testosterone ester~~ of from 1 : 100 to 1 : 1.

PAGE 3/16 * RCVD AT 11/4/2004 4:00:00 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:8729306 * CSID:631 549 0404 * DURATION (mm-ss):03-50

35(previously presented). The method as defined in claim 34, wherein said ratio is from 1 : 10 to 1 : 1.5.

36(previously presented). A method of manufacturing a bioadhesive tablet for controlling testosterone blood level in a person for therapeutic purposes, said method comprising embedding testosterone and one or more testosterone ester in an organic polymer in a ratio of 1 : 10 to 1 : 1.5, optionally together with at least one auxiliary agent, by a spray-drying process, so as to form an amorphous active ingredient premix;

wherein said spray-drying process comprises spray-drying a solution of said organic polymer, said testosterone and said one or more testosterone ester and optionally said at least one auxiliary agent in a solvent; and

wherein said one or more testosterone ester comprises a respective carboxylic acid radical with from 1 to 20 carbon atoms.

37(previously presented). The method as defined in claim 36, wherein said solvent is ethanol and said organic polymer is polyvinyl pyrrolidone or hydroxypropylmethylcellulose.

38(previously presented). The method as defined in claim 32 or 36, further comprising mixing said amorphous active ingredient premix with at least one auxiliary ingredient to form a mixture and compressing said mixture to form said bioadhesive tablet.

PAGE 4/16 * RCVD AT 11/4/2004 4:00:00 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:8729306 * CSID:631 549 0404 * DURATION (mm-ss):03-50

39(previously presented). The method as defined in claim 32, further comprising mixing said amorphous active ingredient premix with at least one auxiliary ingredient to form an active ingredient layer mixture, preparing an adhesive layer mixture and compressing the active ingredient layer mixture together with the adhesive layer mixture to form said bioadhesive tablet with a bi-layer structure.

40(previously presented). The method as defined in claim 39, wherein said at least one auxiliary ingredient is selected from the group consisting of binders, fillers, lubricants, surfactants and a disintegration accelerator and said adhesive layer mixture comprises a bioadhesive polymer.

41(previously presented). The method as defined in claim 32 or 36, further comprising mixing said amorphous active ingredient premix with at least one auxiliary ingredient to form an active ingredient layer mixture, preparing at least one other layer mixture including an adhesive layer mixture and compressing the active ingredient layer mixture together with the at least one other layer mixture to form said bioadhesive tablet with a multi-layer structure.

42(currently amended). The method as defined in claim ~~32 or~~ 36, wherein said one or more testosterone ester has an ester group, said one or more testosterone ester is selected according to chain length and steric structure of said ester group, and wherein respective dosages of said testosterone and said one or more testosterone ester in said bioadhesive tablet is or are selected, so

PAGE 5/16 * RCVD AT 11/4/2004 4:00:00 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:8729306 * CSID:631 549 0404 * DURATION (mm-ss):03-50

that a predetermined testosterone blood level pattern is provided when said bioadhesive tablet is administered to said person.

43(currently amended). The method as defined in claim ~~32 or~~ 36, wherein said one or more testosterone ester is selected from the group consisting of testosterone acetate, testosterone propionate, testosterone enantate, testosterone cipionate, testosterone cyclohexanecarboxylate, testosterone undecanoate and testosterone bucyclate, so that said testosterone blood level in said person varies according to an endogenous circadian body rhythm when said bioadhesive tablet is administered to said person.

44(currently amended). The method as defined in claim ~~32 or~~ 36, wherein said one or more testosterone ester includes testosterone undecanoate and wherein said testosterone and said testosterone undecanoate are embedded together in said organic polymer, in order to provide an extended time-release half-life.

45(currently amended). A bioadhesive tablet for controlling testosterone blood level in a person for therapeutic purposes, said bioadhesive tablet being made by a method comprising embedding testosterone undecanoate alone or a mixture of testosterone undecanoate and testosterone in ~~and/or one or more testosterone ester, separately or together, in~~ an organic polymer, optionally together with at least one auxiliary agent, by a spray-drying process, so as to form an amorphous active ingredient premix~~premix;~~

PAGE 6/16 * RCVD AT 11/4/2004 4:00:00 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:8729306 * CSID:631 549 0404 * DURATION (mm-ss):03-50

~~wherein said one or more testosterone ester comprises a respective carboxylic acid radical with from 1 to 20 carbon atoms~~.

46(canceled).

47(currently amended). The tablet as defined in claim 45, wherein said amorphous active ingredient premix comprises said mixture of said testosterone undecanoate and said testosterone ~~and said one or more testosterone ester~~ in a ratio of said testosterone to said testosterone undecanoate ~~one or more testosterone ester~~ of from 1 : 100 to 1 : 1.

48(previously presented). The tablet as defined in claim 47, wherein said ratio is from 1 : 10 to 1 : 1.5.

49(previously presented). A bioadhesive tablet for controlling testosterone blood level in a person for therapeutic purposes, said bioadhesive tablet being made by a method comprising embedding testosterone and one or more testosterone ester in a ratio of 1 : 10 to 1 : 1.5 in an organic polymer, optionally together with at least one auxiliary agent, by a spray-drying process, so as to form an amorphous active ingredient premix;

wherein said spray-drying process comprises spray-drying a solution of said organic polymer, said testosterone and said one or more testosterone ester and optionally said at least one auxiliary agent in a solvent; and

PAGE 7/16 * RCVD AT 11/4/2004 4:00:00 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:8729306 * CSID:631 549 0404 * DURATION (mm-ss):03-50

wherein said one or more testosterone ester comprises a respective carboxylic acid radical with from 1 to 20 carbon atoms.

50(previously presented). The tablet as defined in claim 49, wherein said solvent is ethanol and said organic polymer is polyvinyl pyrrolidone or hydroxypropyl-methylcellulose.

51(currently amended). The tablet as defined in claim ~~45 or~~ 49, wherein said method comprises mixing said amorphous active ingredient premix with at least one auxiliary ingredient to form a mixture and compressing said mixture to form said bioadhesive tablet.

52(currently amended). The tablet as defined in claim ~~45 or~~ 49, wherein said method comprises mixing said amorphous active ingredient premix with at least one auxiliary ingredient to form an active ingredient layer mixture, preparing an adhesive layer mixture and compressing the active ingredient layer mixture together with the adhesive layer mixture to form said bioadhesive tablet with a bi-layer structure.

53(currently amended). The tablet as defined in claim ~~45 or~~ 49, wherein said method comprises mixing said amorphous active ingredient premix with at least one auxiliary ingredient to form an active ingredient layer mixture, preparing at least one other layer mixture including an adhesive layer mixture and

PAGE 8/16 * RCVD AT 11/4/2004 4:00:00 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:8729306 * CSID:631 549 0404 * DURATION (mm-ss):03-50

compressing the active ingredient layer mixture together with the at least one other layer mixture to form said bioadhesive tablet with a multi-layer structure.

Claims 54 to 65 (canceled).

PAGE 9/16 * RCVD AT 11/4/2004 4:00:00 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:8729306 * CSID:631 549 0404 * DURATION (mm-ss):03-50